Tracer Biotechnologies and AstraZeneca have announced an agreement on a multi-year project in which AstraZeneca will use Tracer's circulating tumor DNA (ctDNA) monitoring technology for clinical trials.
Tracer’s proprietary platform for tumor-informed ctDNA detection uses digital polymerase chain reaction (dPCR); it enables cost-effective, precise, and scalable testing for patients as an alternative to radiographic imaging, the firms said in a statement.
The Tracer assay, which is available for both blood and urine, is the only ultrasensitive ctDNA assay available for molecular response surveillance, according to the company. The companies note that combining tumor-informed personalization with dPCR allows Tracer to offer cost-effective assays for an unlimited number of timepoints during a study.
